Daratumumab for pure red cell aplasia post ABO incompatible allogeneic hematopoietic stem cell transplant for aplastic anemia.
Blood Cells Mol Dis
; 88: 102464, 2021 05.
Article
em En
| MEDLINE
| ID: mdl-32653327
ABSTRACT
Pure red cell aplasia is a known complication after ABO incompatible stem cell transplant. Due to rarity of disease, no established treatment guidelines are available for PRCA. Daratumumab is a monoclonal antibody against CD38 expressed by plasma cells. In this report we present our experience of successfully managing a patient of post-transplant PRCA with daratumumab. Our patient had failed multiple lines of therapy prior to receiving daratumumab. Response was seen after the 3rd weekly dose of daratumumab.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Incompatibilidade de Grupos Sanguíneos
/
Sistema ABO de Grupos Sanguíneos
/
Aplasia Pura de Série Vermelha
/
Transplante de Células-Tronco Hematopoéticas
/
Antineoplásicos Imunológicos
/
Anticorpos Monoclonais
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article